Literature DB >> 8844780

Calcitonin gene-related peptide (CGRP) induces more potent vasorelaxation in the resistance portion than in the conduit portion of mesenteric arteries in humans.

T Miyauchi1, Y Tomobe, T Ishikawa, K Goto, Y Sugishita.   

Abstract

Although physiological processes related to vascular function differ greatly between resistance arteries and conduit arteries, it is not known whether the effects of calcitonin gene-related peptide (CGRP), a vasodilator neuropeptide, on these arteries differ in humans. In the present study, the conduit portion and the resistance portion of isolated human mesenteric arteries were suspended in a Krebs-Ringer solution. CGRP produced vasorelaxations in both portions. The EC50 values were very low both in the resistance portion (2.4 x 10(-9) M, n = 7) and in the conduit portion (2.2 x 10(-9) M, n = 7). The maximum response to CGRP in the resistance portion was significantly greater than that in the conduit portion (94.6 +/- 4.0% vs. 64.1 +/- 2.6% relaxation of methoxamine-induced precontraction, both n = 7, p < 0.01). These data suggest that CGRP is one of the most potent endogenous vasodilators in both the resistance portion and the conduit portion of the human mesenteric arteries, and that CGRP induces more potent vasorelaxation in the resistance portion than in the conduit portion of these arteries.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8844780     DOI: 10.1016/0196-9781(96)00076-9

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  2 in total

1.  Age-related changes in dorsal root ganglia, circulating and vascular calcitonin gene-related peptide (CGRP) concentrations in female rats: effect of female sex steroid hormones.

Authors:  Pandu R R Gangula; Madhu Chauhan; Luckey Reed; Chandra Yallampalli
Journal:  Neurosci Lett       Date:  2009-03-05       Impact factor: 3.046

2.  Sodium channel Nav1.7 in vascular myocytes, endothelium, and innervating axons in human skin.

Authors:  Frank L Rice; Phillip J Albrecht; James P Wymer; Joel A Black; Ingemar Sj Merkies; Catharina G Faber; Stephen G Waxman
Journal:  Mol Pain       Date:  2015-05-09       Impact factor: 3.395

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.